Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets noninvasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Masimo reports robust Q4 earnings, eyes new product launches

Masimo's Q4 2022 earnings call highlighted strong financial performance, growth projections for 2023, and a focus on innovation and regulatory advancements. While facing challenges like supply chain issues and legal disputes, the company remains optimistic about opportunities in new product launches and revenue growth drivers. Overall, Masimo is poised for continued success in the healthcare market.

Masimo reports robust Q1 earnings, navigates challenges with strategic focus

Masimo's Q1 performance reflects strong revenue growth and product innovation, underpinned by a focus on healthcare technology and wearables for chronic illness monitoring.
While facing challenges such as litigation costs and regulatory clearances, Masimo maintains its financial guidance for 2023, signaling stability and strategic resilience.
The company's emphasis on new product launches, diverse pricing strategies, and global market expansion positions it well to capitalize on opportunities in the healthcare sector.

Masimo faces revenue challenges in Q2 but eyes rebound

Masimo's Q2 performance was impacted by revenue challenges in Healthcare and non-healthcare segments, leading to a revised revenue guidance for 2023.
The company is focusing on expense control measures, new product opportunities, and pricing discipline to drive profitability and rebound in business segments.
Despite challenges, Masimo remains optimistic about market opportunities in telehealth, consumer health, and the potential for revenue growth from products like Stork.
Ongoing litigation with Apple and uncertainties in customer order patterns pose challenges, but the company is implementing strategies to address these issues.

Masimo reports solid Q3 earnings, eyes growth in consumer health

Masimo's Q3 performance showcased strong revenue but challenges in sensor utilization recovery. The company's innovative products and expansion into consumer health signal growth potential. Addressing challenges in revenue guidance and market competition will be key focus areas for future success.

Masimo reports robust Q4 earnings, legal wins and growth opportunities

Masimo's strong Q4 performance and strategic focus on healthcare and hearables/wearables growth position the company well for 2024.
Legal victories in Apple litigation and FDA clearances for innovative products underscore Masimo's commitment to innovation and protecting its intellectual property.
While facing challenges in legal proceedings and product clearances, Masimo has opportunities to drive revenue growth through product innovation and market expansion.

Masimo reports strong Q1 earnings, plans consumer business separation

Masimo's Q1 2024 Earnings Call showcased robust financial performance, strategic revenue diversification, and plans for enhancing shareholder value through potential separation of the consumer business. While facing challenges in operational transitions and financial metrics scrutiny, the company is well-positioned for growth and value creation.

Masimo reports robust Q3 performance and outlines growth opportunities

Masimo's Q3 2024 earnings call showcased strong financial performance, strategic reviews, and growth initiatives. While facing challenges in margin progression and potential disruptions, the company is poised for growth with opportunities in revenue expansion and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) today announced its financial results for the second quarter of 2023, ended July 1, 2023. Second Quarter 2023 Financial Results Consolidated revenue was $455.3 million, comprised of healthcare revenue of $281.1 million and non-healthcare revenue of $174.2 million. Shipments of noninvasive technology boards and instruments were 64,100. Consolidated GAAP operating income was $29.3 million. Consolidated non-GAAP operating income wa.

Masimo Reports Second Quarter 2023 Financial Results

LOS ANGELES, CA / ACCESSWIRE / August 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Masimo Corporation ("Masimo" or "the Company") (NASDAQ:MASI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Masimo Corporation and Encourages Investors with Losses to Contact the Firm

IRVINE, Calif.--(BUSINESS WIRE)--Masimo SedLine® PSi better captured changes in brain state during dexmedetomidine anesthesia than other assessment methods in a new study.

New Study Finds That Masimo SedLine® Patient State Index (PSi) Has the Potential to Improve Brain Monitoring for Patients Sedated with Dexmedetomidine

LOS ANGELES, CA / ACCESSWIRE / August 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Masimo Corporation ("Masimo" or "the Company") (NASDAQ: MASI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Masimo Corporation and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Masimo Corporation ("Masimo" or "the Company") (NASDAQ:MASI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Masimo Corporation and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Masimo Corporation ("Masimo" or "the Company") (NASDAQ:MASI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Masimo Corporation and Encourages Investors with Losses to Contact the Firm

NEW YORK , Aug. 1, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Masimo Corporation ("Masimo") (NASDAQ: MASI) violated federal securities laws. CURRENT INVESTIGATION DETAILS:On July 17, 2023, Masimo issued a press release announcing its preliminary revenue results for the second quarter of 2023.

MASI NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Masimo Corporation

NEW YORK , July 31, 2023 /PRNewswire/ -- Attention Masimo Corporation ("Masimo") (NASDAQ: MASI) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into Masimo and certain of its officers and directors regarding potential securities fraud. The investigation concerns, in part, the below: On July 17, 2023, Masimo issued a press release announcing its preliminary revenue results for the second quarter of 2023.

MASI ALERT: The Law Offices of Vincent Wong Investigate Masimo Corporation for Potential Violations of Securities Laws

LOS ANGELES, CA / ACCESSWIRE / July 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Masimo Corporation ("Masimo" or "the Company") (NASDAQ:MASI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Masimo Corporation and Encourages Investors with Losses to Contact the Firm

NEW YORK , July 28, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Masimo Corporation (NASDAQ: MASI) To be contacted by a member of our team, fill out the form: https://claimyourloss.com/securities/masimo-class-action-loss-submission-form/?id=42679&from=4 Further details on the investigation: On July 17, 2023, Masimo issued a press release announcing its preliminary revenue results for the second quarter of 2023. Masimo advised that it anticipates revenue of between $453 million and $457 million for the quarter, significantly less than the $540.87 million consensus estimate.

MASI FRAUD ALERT: Jakubowitz Law is Investigating Masimo Corporation in Connection with Potential Violations of Federal Securities Laws

NEW YORK , July 26, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Masimo Corporation: On July 17, 2023, Masimo issued a press release announcing its preliminary revenue results for the second quarter of 2023. Masimo advised that it anticipates revenue of between $453 million and $457 million for the quarter, significantly less than the $540.87 million consensus estimate.

INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Masimo Corporation of an Investigation and Potential Class Action Lawsuit - (NASDAQ: MASI)

LOS ANGELES, CA / ACCESSWIRE / July 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Masimo Corporation ("Masimo" or "the Company") (NASDAQ:MASI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Masimo Corporation and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Masimo's (MASI) second-quarter 2023 results are likely to have been dampened by the postponement of orders and increased hospital labor costs, among others.

Masimo's (MASI) Preliminary Q2 Revenues Dampened by Lower Sales

Masimo cut its guidance for the second quarter and the year. The company is seeing a slowdown in orders from hospitals.

Why Shares of Masimo Are Dropping Tuesday

Masimo preannounced light second-quarter sales Tuesday and investors hammered MASI stock, sending it to a five-year low.

Masimo Plummets To Five-Year Low On Light Sales, 'Longer-Term' Challenges Persist

Masimo (NASDAQ: MASI ) stock is taking a beating on Tuesday after the patient monitoring tech company released preliminary earnings for Q2 2023. The bad news for investors in MASI stock starts with its expected revenue of $453 million to $457 million for the second quarter of the year.

Why Is Masimo (MASI) Stock Down 30% Today?

Masimo shares plunged almost 30% in pre-market trading on Tuesday after it reported preliminary second quarter revenue that came in far below expectations. The Irvine, California-based medical technology company expects 2Q revenue to range from $453 million to $457 million, below the Street's forecast of $553.2 million, according to Refinitiv.

Masimo shares plummet on weak 2Q sales forecast

Pinterest

Shares of Pinterest Inc. PINS, +1.53% were gaining 4% after an Evercore ISI analyst moved to a bullish stance, cheering better advertising-market conditions and improvements made by Chief Executive Bill Ready, who is about a year into his stint.

Pinterest stock advances, Masimo shares slump on outlook and other stocks on the move

Shares of Masimo Corp. MASI, -1.61% on Monday tumbled 25% after hours after the hospital-equipment maker forecast second-quarter sales that were far below estimates and tempered sales expectations for the full year, amid delayed orders, fewer hospital patients and other issues. Executives at the company, which makes patient-monitoring technology, said they expected Masimo's second-quarter revenue to come in between $453 million and $457 million, below FactSet forecasts for $553 million.

Weaker sales due to fewer hospital patients take down shares of Masimo

Masimo Corp on Monday reported preliminary second-quarter results below analysts' estimates, sending the medical device maker's shares down about 20% in after-market trading.

Medical device maker Masimo forecasts weak quarterly revenue

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) today announced preliminary revenue results for the second quarter ended July 1, 2023. Preliminary Second Quarter 2023 Revenue Results Masimo expects its consolidated revenue for the second quarter 2023 to range from $453 million to $457 million, with healthcare revenue expected to range from $280 million to $282 million and non-healthcare revenue expected to range from $173 million to $175 million. Though the healthcare busines.

Masimo Announces Preliminary Second Quarter 2023 Revenue Results

Masimo's (MASI) solid product suite raises optimism about the stock.

Three Reasons to Add Masimo (MASI) Stock to Your Portfolio

NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), a 9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today commented on the outcome of the Company's Annual Meeting of Stockholders (the “Annual Meeting”). Both of Politan's nominees – Michelle Brennan and Quentin Koffey – were overwhelmingly elected to the Board. Based on preliminary analysis from Politan's proxy solicitor, each of Politan's nominees received at least.

Politan Announces Shareholders Have Overwhelmingly Elected Both Its Director Nominees to Masimo's Board

Masimo's (MASI) W1 advanced health-tracking watch is expected to provide better insights into pre-operative patients' heart rate variability data and improve pre-habilitation.

Masimo's (MASI) W1 to Boost Virtual Care in Preoperative Patients

Masimo's (MASI) new product offerings are expected to enable it to expand its footprint in the personalized hearables market.

News for Masimo Stock (MASI)